Evidence map›Paper›PMID 41462488›Full record

ArticleCell & bioscience2025

Recombinant attenuated Salmonella vaccine promotes CD8

Jae-Hyeon Jeong, Dae-Joon Kim, Chae-Won Kim, Youngjoo Han, Ah-Ra Jang, Jong-Hwan Park, Nara Tae, Jae-Hee Ahn, Jaewon Cho, Sun Shim Choi and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell & bioscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. AttenuatedFrontiers in immunology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Jae-Hyeon Jeong *Laboratory of Microbiology and Immunology, Department of Pharmacy, College of Pharmacy, Kangwon National University, 1, Kangwondaehak-Gil, Chuncheon, 24341, Republic of Korea.
Dae-Joon Kim *Laboratory of Microbiology and Immunology, Department of Pharmacy, College of Pharmacy, Kangwon National University, 1, Kangwondaehak-Gil, Chuncheon, 24341, Republic of Korea.
Chae-Won KimLaboratory of Microbiology and Immunology, Department of Pharmacy, College of Pharmacy, Kangwon National University, 1, Kangwondaehak-Gil, Chuncheon, 24341, Republic of Korea.
Youngjoo HanLaboratory of Microbiology and Immunology, Department of Pharmacy, College of Pharmacy, Kangwon National University, 1, Kangwondaehak-Gil, Chuncheon, 24341, Republic of Korea.
Ah-Ra JangNodcure Inc., 77 Yongbong-Ro, Buk-Gu, Gwangju, 61186, Republic of Korea.
Jong-Hwan ParkLaboratory Animal Medicine, College of Veterinary Medicine and Animal Medical Institute, Chonnam National University, Gwangju, 61186, Republic of Korea.
Nara TaeKangwon Institute of Inclusive Technology, Kangwon National University, Chuncheon, 24341, Republic of Korea.
Jae-Hee AhnLaboratory of Microbiology and Immunology, Department of Pharmacy, College of Pharmacy, Kangwon National University, 1, Kangwondaehak-Gil, Chuncheon, 24341, Republic of Korea.
Jaewon ChoLaboratory of Microbiology and Immunology, Department of Pharmacy, College of Pharmacy, Kangwon National University, 1, Kangwondaehak-Gil, Chuncheon, 24341, Republic of Korea.
Sun Shim ChoiDivision of Biomedical Convergence, College of Biomedical Science, Institute of Bioscience & Biotechnology, Kangwon National University, Chuncheon, 24341, Republic of Korea.
Mi-Na KweonDepartment of Convergence Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, 05505, Republic of Korea.
Dae Hee KimLaboratory of Microbiology and Immunology, Department of Pharmacy, College of Pharmacy, Kangwon National University, 1, Kangwondaehak-Gil, Chuncheon, 24341, Republic of Korea. kimdh@kangwon.ac.kr.
Hyun-Jeong KoLaboratory of Microbiology and Immunology, Department of Pharmacy, College of Pharmacy, Kangwon National University, 1, Kangwondaehak-Gil, Chuncheon, 24341, Republic of Korea. hjko@kangwon.ac.kr.ORCID http://orcid.org/0000-0002-3844-928X

Funding

National Research Foundation of Korea 2020R1A5A8019180National Research Foundation of Korea RS-2023-00208385
6 · The paper itself

Abstract

backgroundCancer is a leading cause of mortality worldwide, necessitating the development of novel therapeutic targets and strategies to prevent recurrence and metastasis. In this study, we aimed to evaluate whether a recombinant attenuated Salmonella vaccine (RASV) can stimulate antitumor immunity and prevent cancer progression in vivo.

methodsWe established a mouse model by transplanting cancer cells subcutaneously 4 weeks after oral RASV inoculation and analyzed bone marrow (BM) cells and tumor-infiltrated immune cells by flow cytometry. Further, we established a 4 T-1-induced metastatic cancer model to evaluate the RASV-mediated prevention of tumor metastasis.

resultsAdjuvant RASV significantly reduced tumor growth by enhancing CD8

conclusionsRASV inoculation can promote marked alterations in the BM microenvironment, thus reshaping the anticancer immune response in vivo. This strategy holds therapeutic potential for preventing cancer recurrence and metastasis.

Indexed as

Antitumor immune responseBone marrowCommon lymphoid progenitor cellsMetastasisRecombinant attenuated Salmonella vaccine

Identifiers

PMID41462488
PMCPMC12752189

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.